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Abstract
Background: Fabry patients have symptoms and signs compatible with autonomic dysfunction. These symptoms and 
signs are considered to be due to impairment of the peripheral nervous system, but findings indicative of autonomic 
neuropathy in other diseases, such as orthostatic intolerance and male sexual dysfunction, are infrequently reported in 
Fabry disease. The aim of our study was to investigate autonomic symptoms and cardiovascular autonomic function in 
a large cohort of male and female Fabry patients.
Methods: Forty-eight Fabry patients (15 male, 30 treated with enzyme replacement therapy) and 48 sex- and age-
matched controls completed a questionnaire on autonomic symptoms (the Autonomic Symptom Profile). Thirty-six 
Fabry patients underwent cardiovascular function tests.
Results: The Autonomic Symptom Profile revealed a significantly higher sum score in Fabry patients than in healthy 
control subjects (22 versus 12), but a relatively low score compared to patients with proven autonomic neuropathy. 
Fabry patients scored worse than healthy controls in the orthostatic intolerance domain. Scores in the male sexual 
dysfunction domain were comparable between healthy controls and male Fabry patients. The cardiovascular 
autonomic function tests revealed only mild abnormalities in seven patients. None of these seven patients showed 
more than one abnormal test result. Enzyme replacement therapy was not associated with less severe disease, lower 
ASP scores or less frequent abnormal cardiovascular function test results.
Conclusions: Male sexual function and autonomic control of the cardiovascular system are nearly normal in Fabry 
patients, which cast doubt on the general accepted assumption that autonomic neuropathy is the main cause of 
symptoms and signs compatible with autonomic dysfunction in Fabry disease. Possibly, end-organ damage plays a key 
role in the development of symptoms and signs in Fabry patients. An exceptional kind of autonomic neuropathy is 
another but less likely explanation.
Background
Fabry disease (OMIM 301500) is an X-linked glycolipid
storage disease caused by deficient activity of the lyso-
somal enzyme α-galactosidase-A leading to lysosomal
accumulation of globotriaosylceramide and subsequently
to severe multi-system disease. Male patients are usually
severely affected, but symptoms and signs often appear
also in female carriers. They consist of skin lesions
(angiokeratomas), corneal opacities, cardiac hypertrophy
and rhythm disturbances, renal failure, acroparesthesias,
defective sweating (hypo- or anhidrosis), abdominal pain
and diarrhoea.
Abnormalities of tears and saliva formation, cardiac
rhythm disturbances, defective sweating and gastrointes-
tinal complaints have frequently been explained by auto-
nomic failure. As several studies have shown small fibre
damage [1,2] and accumulation of lipids in the autonomic
ganglia in Fabry patients [3], symptoms and signs com-
patible with autonomic dysfunction have generally been
* Correspondence: c.e.hollak@amc.uva.nl
4 Department of Internal Medicine, Division of Endocrinology and Metabolism, 
Academic Medical Center, Amsterdam, the Netherlands
Full list of author information is available at the end of the articleBiegstraaten et al. BMC Neurology 2010, 10:38
http://www.biomedcentral.com/1471-2377/10/38
Page 2 of 9
attributed to autonomic neuropathy [4-6]. However,
more recently, an- or hypohydrosis has been found to be
due to sweat gland dysfunction rather than autonomic
neuropathy [7].
Autonomic involvement occurs in a wide range of
peripheral neuropathies, albeit with variable symptoma-
tology. Orthostatic intolerance and male sexual dysfunc-
tion, however, are invariably found in autonomic
neuropathies [8]. Surprisingly, these symptoms are infre-
quently reported in Fabry disease. Symptom surveys that
systematically investigated the presence of orthostasis
and impotence in Fabry patients are lacking. Data
obtained from the Fabry Outcome Survey (FOS), a Euro-
pean outcomes database of clinical manifestations in
Fabry patients, revealed only a limited number of cases
with orthostatic intolerance [9], while male sexual dys-
function was not recorded at all. Only few studies investi-
gating cardiovascular autonomic function have been
carried out in Fabry patients. Heart rate variability has
been tested in small numbers of Fabry patients and
showed abnormal results in two studies [10,11] while oth-
ers did not find decreased heart rate variability [12].
None of the studied Fabry patients had orthostatic
hypotension [6,12].
Altogether, symptoms and signs compatible with auto-
nomic dysfunction in Fabry disease are considered to be
due to autonomic neuropathy, while studies focusing on
typical symptoms and signs are scarce. The main objec-
tive of this study was to investigate the presence of auto-
nomic neuropathy with emphasis on autonomic
symptomatology and impaired cardiovascular auto-
nomic control in Fabry patients.
Methods
The Academic Medical Center (AMC) is the single refer-
ral center for the treatment of Fabry patients in the Neth-
erlands. All male and female Fabry patients aged 12 years
and older who visit the outpatient pediatric or adult clinic
for inherited metabolic diseases at the AMC were asked
to participate. In all patients a diagnosis of Fabry disease
was confirmed by enzymatic assay or DNA mutation. The
study was approved by the local Ethics Committee and all
patients (and parents if applicable) provided written
informed consent.
To measure the severity of Fabry disease in individual
patients, the Mainz Severity Score Index (MSSI) was used
[13]. Patients with a total score of less than 20 are defined
to be mildly affected, those with a score from 20-40 are
moderately affected, and those with a score above 40 are
severely affected [14]. Pain intensity was assessed on an
11-point visual analogue scale (VAS), anchored no pain
(0) and worst possible pain (10). Patients were asked to
score their most severe pain in the last 4 weeks [15].
Presence and severity of autonomic symptoms were
assessed using the Autonomic Symptom Profile (ASP)
[16]. This questionnaire consists of 73 items on different
aspects of autonomic dysfunction and has 11 weighted
subscale scores, including an orthostatic intolerance and
a male sexual dysfunction subscale. The total score is the
calculated sum of the 11 individual subscales, giving a
maximum score of 200 for males and of 170 (200 minus
30 for the male sexual dysfunction scale) for females. A
score of zero means no complaints. A higher score indi-
cates more or worse symptoms. Originally this instru-
ment was tested in three different groups: healthy
controls, patients with all kinds of non-autonomic
p e r i p h e r a l  n e u r o p a t h y  a n d  p a t i e n t s  w i t h  p r o v e n  a u t o -
nomic neuropathy [16]. Healthy controls had a mean sum
score of 10, patients with non-autonomic peripheral neu-
ropathy had a mean score of 26, and patients with proven
autonomic neuropathy had on average a score of 52. The
latter scored on average 21.6 (score more than zero: 90%)
in the orthostatic intolerance domain and 9.5 (score more
than zero: 71%) in the male sexual dysfunction domain.
Scores obtained from our patients were compared with
these scores and with scores obtained from a sample of 48
sex- and age-matched healthy hospital workers who were
asked for their co-operation by one of the authors (MB).
Furthermore, patients underwent cardiovascular auto-
nomic function tests that were based on the guidelines
designed for the detection of diabetic autonomic dys-
function and formulated by diabetes specialists in 1992 at
the San Antonio Conference on Diabetic Neuropathy
[17]. According to this conference an abnormality on
more than one test is desirable to establish the presence
of autonomic dysfunction.
In this study a forced breathing test and a standing up
test from supine were performed. Changes in heart rate
and blood pressure induced by forced breathing and
standing up were assessed and compared to control val-
ues for these changes. Lower limits of normal (2.5 per-
centile) per age-group have been well-established in our
laboratory [18]. The forced breathing test was performed
in supine position. After 5 minutes rest the patient was
instructed to perform six consecutive maximal inspira-
tion and expiration cycles at a rate of 6 breaths per min-
ute. To quantify the test score, the difference between
maximal and minimal heart rate for each of the six cycles
was determined and averaged to obtain the Inspiratory-
Expiratory (I-E) difference in beats per minute [18]. After
standing up, heart rate increases. The highest heart rate
in the first 15 seconds from the onset of standing was
determined and expressed as the increase from baseline
(ΔHRmax). We used the highest and lowest heart rate in
the first 30 seconds from the onset of standing to quantify
the relative bradycardia (HRmax/HRmin ratio). Heart
rate and finger blood pressure at 3 minutes after theBiegstraaten et al. BMC Neurology 2010, 10:38
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change of posture were measured. A persistent fall of
more than 20 mmHg in systolic pressure after 3 minutes
standing and a fall of more than 10 mmHg in diastolic
pressure after 3 minutes standing were considered to be
abnormal.
Statistical analysis
All results are expressed by mean and standard deviation
or median and range where appropriate. Differences
between variables are calculated using the unpaired t-test
or Mann Whitney test and differences in proportions are
tested using the Fisher's exact test. Correlations between
variables are described with the use of Spearman correla-
tion coefficients (Spearman's rho). Significance is defined
at a p-value of < 0.05.
Results
A total of 70 Fabry patients are followed at regular inter-
vals at the outpatient pediatric or adult clinic for inher-
ited metabolic diseases at the AMC. All patients were
asked to participate in the study. Two adult patients could
not be reached by phone and 15 adult patients refused to
participate. Travel distance was the most frequently men-
tioned reason. Another 5 children did not take part in the
study, mostly as their parents considered participation as
too demanding. Half of the 22 non-participating patients
were male. The median age was significantly lower than
that of the participating patients (29 years, p = 0.008) but
the MSSI was not different (median sum score 12.5, p =
0.74) at the time the study started.
In total, 48 patients (69% of the Dutch Fabry popula-
tion) were included. In Table 1 the patient characteristics
are shown. Thirty patients received enzyme replacement
therapy (ERT) with a median duration of 3.6 years (range
0.2-6.0). Other frequently prescribed medications were:
pain medication (11 patients of whom 1 used non-steroi-
dal pain medication), ACE inhibitors (10 patients), ATII-
antagonists (11 patients), beta blockers (3 patients) and
diuretics (9 patients).
The MSSI sum score revealed that on average male
patients were moderately affected and females were
mildly affected. Twenty-nine patients scored below 20
(mildly affected), 18 patients scored between 20-40
(moderately affected) and only 1 male patient had a sum
score of more than 40 (severely affected) [14]. The
median score for most severe pain in the last 4 weeks was
3 (range 0-9). This score did not differ significantly
between male and female patients.
All patients completed the ASP. Table 2 shows median
scores per domain. In Table 3 the numbers of patients
with a score of more than zero for the different domains
are shown. The median ASP sum score for all patients
was 22 (range 0-78). Male patients had a median score of
18 out of 200 points and female patients scored 24 out of
170 points. Neither these scores (p = 0.71), nor the scores
of the different domains differed between males and
females. Controls (15 males, 33 females, median age 46
years, range 14-74) had a median score of 12 (range 0-35),
which was better than Fabry patients (p = 0.005).
Median scores in the orthostatic intolerance domain
were 13 (range 0-35) for Fabry patients and 1.3 (range 0-
25) for healthy controls (p = 0.004). Seventy-five percent
of the Fabry patients scored more than zero points in this
domain compared with 50% of the healthy controls (p =
0.02). Median scores in the male sexual failure domain
were 0 (range 0-17) for Fabry patients and 0 (range 0-7.5)
for healthy controls (p = 0.29). Forty percent of male
Fabry patients scored more than zero points in this
domain compared with 20% of healthy male controls (p =
0.43). Furthermore, unexpectedly low numbers of Fabry
patients scored more than zero points in the secretomo-
tor, gastroparesis, diarrhoea and constipation domains,
being respectively 28, 15, 13 and 10.
Spearman correlation did not show a relationship
between age and the ASP sum score (Spearman's rho =
0.14, p = 0.35) and a trend towards an association
between the MSSI sum score and ASP sum score was
found (Spearman's rho = 0.27, p = 0.06).
Thirty-six patients (10 males and 26 females, 75% of the
study population) underwent autonomic cardiovascular
function tests. Twelve patients refused to make an extra
visit to the hospital for the purpose of this study. In two
cases heart rate variability (HRV) was impossible to
assess due to frequent extrasystoles. The results of these
tests are summarized in Table 4 and Figure 1.
Three female patients aged 25, 50 and 53 years old and
with MSSI sum scores of 13, 24 and 17 showed abnormal
results of the forced breathing test. They scored respec-
tively 12, 9 and 9 beats per minute indicating a decreased
HRV. The ECG of the 50-year-old woman showed signs
of left ventricular hypertrophy (LVH) and the 53-year-old
woman suffered from cardiomyopathy. Three males aged
25, 52 and 63 years old and with MSSI sum scores of 13,
27 and 47 had an abnormal initial heart rate response to
standing up from supine position. The first was known
with LVH and the latter with cardiomyopathy, while the
52-year-old male did not have cardiac pathology. They
scored respectively 17, 11 and 11 beats per minute which
are abnormally low scores in relation to their age. One 14-
year-old girl with an MSSI sum score of 2 had a persistent
fall of 11 mmHg in diastolic pressure 3 minutes after
standing up.
Role of ERT
Two of the 15 male study patients were untreated. They
were similar to ERT treated patients with respect to age
and disease severity. Female patients who were treated
with ERT were older and more severely affected com-B
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Table 1: Patient characteristics.
All patients
n = 48
Male patients
n = 15
non-ERT
n = 2
ERT
n = 13
non-ERT versus 
ERT, p-value
Female patients
n = 33
non-ERT
n = 16
ERT
n = 17
non-ERT versus 
ERT, p-value
Age, years median (range) 47 (12-73) 47 (21-66) 47.5 (46-49) 47 (21-66) 1.00 45 (12-73) 25.5 (12-52) 51 (22-73) 0.00
Enzyme activity, μmol/l/h median 
(range)
14 (0.0-59) 1.2 (0.0-6.4) 2.0 (1.5-2.5) 0.7 (0.0-6.4) 0.20 19.6 (4.1-59.3) 20 (13-51) 19 (4.1-59) 0.51
MSSI sum score median (range) 15.5 (1-47) 25 (5-47) 11 (5-17) 27 (10-47) 0.23 13 (1-35) 7 (1-18) 23 (3-35) 0.00
general score median (range) 4 (0-11) 5 (2-11) 3.5 (2-5) 5 (2-11) 0.31 4 (0-8) 2 (0-5) 5 (1-8) 0.00
neurological score median 
(range)
4 (0-13) 6 (0-13) 0.5 (0-1) 6 (3-13) 0.02 3 (0-12) 1.5 (0-7) 4 (1-12) 0.04
cardiovascular score median 
(range)
6.5 (0-15) 9 (1-15) 7 (3-11) 9 (1-15) 0.69 4 (0-15) 1.5 (0-11) 9 (0-15) 0.07
renal score median (range) 0 (0-12) 0 (0-12) 0 0 (0-12) 0.38 0 (0-12) 0 4 (0-12) 0.00
VAS most severe pain median 
(range)
3 (0-9) 4 (0-8) 1 4 (0-8) 0.31 2 (0-9) 0.5 (0-8) 5 (0-9) 0.20
n = 36 n = 10 n = 2 n = 8 n = 26 n = 9 n = 17
Systolic BP, mmHg mean (SD) 118 (12) 114 (13) 115 (20) 113 (13) 0.88 120 (11) 115 (8) 123 (12) 0.11
Diastolic BP, mmHg mean (SD) 71 (7) 71 (9) 74 (16) 70 (8) 0.68 71 (7) 70 (9) 72 (5) 0.46
Heart rate, bpm mean (SD) 65 (12) 68 (13) 61 (4) 70 (14) 0.40 64 (12) 66 (13) 63 (11) 0.47
ERT = enzyme replacement therapy, MSSI = Mainz Severity Score Index, VAS = visual analogue scale, BP = blood pressure, bpm = beats per minuteBiegstraaten et al. BMC Neurology 2010, 10:38
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pared with untreated females (see Table 1). No difference
in ASP sum score was found between ERT treated and
untreated patients (p = 0.30), while secretomotor prob-
lems and sleep disorder were more frequent and more
severe in ERT treated than untreated patients (see Tables
2 and 3).
Twenty-five of the 36 patients (69%) who underwent
autonomic cardiovascular function tests received ERT.
Patients on ERT had lower heart rate variability than
untreated patients. All three females and three males with
an abnormal heart rate variability test result were treated
with ERT. The 14-year-old girl was untreated. Altogether,
ERT was not associated with less severe disease, lower
ASP scores or less frequent cardiovascular autonomic
function abnormalities.
Discussion
In this study we found a low prevalence of orthostatic
intolerance and male sexual dysfunction in a rather large
cohort of Fabry patients. The cardiovascular autonomic
function tests showed normal cardiovascular autonomic
control in almost all of our Fabry patients.
This raises the important question whether autonomic
neuropathy plays a prominent role in Fabry symptoms
and signs. The disturbances that have been ascribed to
autonomic neuropathy in Fabry disease include an- or
hypohydrosis, decreased tears and saliva formation,
abnormal cerebrovascular reactivity, cardiac rhythm dis-
turbances as well as gastrointestinal complaints [4-6].
However, unlike the findings in other diseases that cause
autonomic neuropathy [8] and in patients with proven
autonomic failure [16], orthostatic intolerance and male
sexual dysfunction are less frequent and less severe mani-
festations in our Fabry patients. Furthermore, the low
resting heart rate as found in our study patients is
unusual in patients with an autonomic neuropathy.
Defective sweating has long been thought to originate
from autonomic neuropathy. However, skin biopsies did
Table 2: Autonomic Symptom Profile scores, median (range).
Domain All patients
n = 48
non-ERT
n = 18
ERT
n = 30
non-ERT versus 
ERT, p-value
Healthy controls
n = 48
Patients versus 
controls, p-value
Orthostatic intolerance 13 (0-35) 14 (0-28) 13 (0-35) 0.96 1.3 (0-25) 0.004
Vasomotor impairment 0 (0-8.2) 0 (0-7.6) 0 (0-8.2) 0.33 0 (0-6.3) 0.017
Secretomotor disorder 1.5 (0-14) 0 (0-7.5) 3 (0-14) 0.000 1.5 (0-7.5) 0.23
Gastroparesis 0 (0-8.4) 0 (0-8.4) 0 (0-5) 0.36 0 (0-3.3) 0.017
Diarrhoea 0 (0-16) 0 (0-8) 0 (0-16) 0.57 0 (0-8) 1.00
Constipation 0 (0-11) 0 (0-6) 0 (0-11) 0.95 0 (0-9) 0.63
Bladder disorder 0 (0-12) 0 (0-10) 0 (0-12) 0.38 0 (0-4) 0.74
Pupillomotor impairment 0.5 (0-4.5) 0.5 (0-2.5) 0.5 (0-4.5) 0.78 0 (0-3) 0.13
Sleep disorder 1.5 (0-7.5) 0 (0-6) 1.5 (0-7.5) 0.002 0 (0-6) 0.06
Syncope 0 (0-4) 0 (0-4) 0 (0-4) 0.29 0 (0-4) 0.31
Sum score 22 (0-78) 21 (0-49) 24 (0-78) 0.30 12 (0-35) 0.005
Male 
patients
n = 15
non-ERT
n = 2
ERT
n = 13
p-value Male controls
n = 15
p-value
Male sexual failure 0 (0-17) 0.8 (0-1.5) 0 (0-17) 0.93 0 (0-7.5) 0.29
ERT = enzyme replacement therapyBiegstraaten et al. BMC Neurology 2010, 10:38
http://www.biomedcentral.com/1471-2377/10/38
Page 6 of 9
not reveal a decrease in nerve fibre density of sweat gland
innervation, but revealed storage of lipids in sweat
glands. Also, the non-length dependent distribution of
the an- or hypohydrosis and the rapid effect of single
enzyme infusions, suggested a sweat gland dysfunction
rather than an autonomic neuropathy [7]. In line with
defective sweating, end-organ failure might also account
for the abnormal peripheral blood flow that has been
found in several studies [19,20]. A study on vascular
hyperreactivity in Fabry disease supports this hypothesis;
absence of a difference in plasma epinephrine or norepi-
nephrine levels between patients and controls suggested
that the altered vessel response in Fabry disease may be
attributed to vasogenic and not to neurogenic factors
[21]. This is further supported by almost normal cardio-
vascular autonomic function, as has been confirmed in
the current study as well as in previous studies [6,12].
Studies on heart rate variability (HRV) in pediatric Fabry
patients revealed significantly different results between
boys and both girls and controls, with significant
improvement of heart rate variability in boys upon ERT
[10,11]. However, it is likely that cardiac pathology (i.e.
left ventricular hypertrophy and/or conduction system
pathology) has influenced the abnormalities observed in
these patients. In the current study, only 6 out of 36 Fabry
patients showed an abnormal HRV on one test. As four of
these six patients were known with LVH or cardiomyopa-
thy, our findings could be partly explained by the underly-
ing cardiac pathology.
Altogether, our results indicate that symptoms and
signs compatible with autonomic dysfunction in Fabry
patients are probably not due to autonomic neuropathy.
More likely, these symptoms and signs are caused by end-
organ failure which has been suggested before by others
[22,23] and is supported by findings from previous stud-
ies [7,21]. An exceptional kind of autonomic neuropathy
can, however, not be totally excluded.
Table 3: Autonomic Symptom Profile Scores, score > 0, n (%).
Domain All patients
n = 48
non-ERT
n = 18
ERT
n = 30
non-ERT versus 
ERT, p-value
Healthy controls
n = 48
Patients versus 
controls, p-value
Orthostatic intolerance 36 (75) 13 (72) 23 (77) 0.74 24 (50) 0.02
Vasomotor impairment 15 (31) 4 (22) 11 (37) 0.35 6 (13) 0.047
Secretomotor disorder 28 (58) 3 (17) 25 (83) 0.00 25 (52) 0.68
Gastroparesis 15 (31) 4 (22) 11 (37) 0.35 6 (13) 0.047
Diarrhoea 13 (27) 6 (33) 7 (23) 0.51 15 (31) 0.82
Constipation 10 (21) 4 (22) 6 (20) 1.00 14 (29) 0.48
Bladder disorder 17 (35) 5 (28) 12 (40) 0.54 18 (38) 1.00
Pupillomotor impairment 29 (60) 12 (67) 17 (57) 0.55 19 (40) 0.07
Sleep disorder 28 (58) 5 (28) 23 (77) 0.00 23 (48) 0.41
Syncope 3 (6) 2 (11) 1 (3) 0.55 1 (2) 0.62
Sum score 46 (96) 17 (94) 29 (97) 1.00 46 (96) 1.00
Male patients
n = 15
non-ERT
n = 2
ERT
n = 13
p-value Male controls
n = 15
p-value
Male sexual failure 6 (40) 1 (50) 5 (38) 1.00 3 (20) 0.43
ERT = enzyme replacement therapyBiegstraaten et al. BMC Neurology 2010, 10:38
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It is surprising that, in spite of evidence of small fibre
neuropathy in Fabry disease [1,2], and autonomic func-
tions being carried by these small nerve fibres, we did not
find symptoms and signs that are generally found in
patients with autonomic neuropathy due to other dis-
eases. Diabetic neuropathy and other small fibre neurop-
athies (i.e. amyloidosis, leprosy and HIV) lead to equal
damage of C and Aδ fibres or to more severe damage of C
fibres than Aδ fibres [24-27]. In contrast, Fabry disease
causes more severe impairment of Aδ fibres compared to
C fibres, as shown by quantitative sensory testing [1,12].
Preganglionic autonomic fibres consist of small myeli-
nated B fibres and postganglionic autonomic fibres are
small unmyelinated C fibres [28]. The relatively selective
damage to 'non-autonomic' small myelinated Aδ fibres in
Fabry disease could therefore underlie the found preser-
vation of autonomic function in Fabry disease. One other
disease, hereditary sensory and autonomic neuropathy
(HSAN) type 5, is known to cause selective loss of small
myelinated nerve fibres. Autonomic function is usually
spared in HSAN type 5; none of the reported patients had
orthostatic hypotension, although anhydrosis has been
reported in some [29]. Apparently, damage to C-fibres is
required for the development of overt autonomic neurop-
athy.
In contrast to orthostatic intolerance and male sexual
dysfunction, gastrointestinal complaints are frequently
reported in Fabry disease. These complaints have been
attributed to dysfunction of enteric neurons [30]. Data
obtained from 342 Fabry patients enrolled in the Fabry
Outcome Survey (FOS), revealed that 60.8% of children
and 49.8% of adults experienced gastrointestinal com-
plaints. The most frequently reported gastrointestinal
symptoms were abdominal pain and diarrhoea [30]. In
this light, the high numbers of patients without gastroin-
testinal disturbances in the current cohort are unex-
pected. This difference between the FOS data and our
results may be due to an overestimation in the FOS as
these findings were based on self-reports by patients, and
not on a validated questionnaire.
F u r t h e r m o r e ,  a n  u n e x p e c t e d l y  l o w  n u m b e r  o f  F a b r y
patients reported secretomotor problems. This may be
attributed to a shortcoming in the questionnaire we used:
the ASP assesses changes in sweating in the past five
years, whereas Fabry patients usually suffer from sweat
problems from childhood on.
Another limitation of the current study is that we
included mainly mild to moderately affected patients. As
we found a trend towards a correlation between the MSSI
sum score and the ASP sum score and relatively high
MSSI sum scores in 4 out of 6 patients with an abnormal
heart rate variability test result, we cannot exclude that
autonomic neuropathy is more prevalent in severely
affected patients. Besides, the cross-sectional character of
the study precludes definite conclusions on the long term
effect of enzyme replacement therapy in individual
patients. However, our results suggest that patients with
relatively severe disease are more often on ERT and that
the severity of autonomic dysfunction is not influenced
by ERT . A final limitation is that we have restricted the
function tests to those evaluating cardiovascular auto-
nomic function. However, abnormalities in the auto-
nomic control of other organ systems such as peripheral
vascular reactivity is thought to reflect end-organ pathol-
ogy and not real autonomic neuropathy as discussed
above.
Conclusions
Male sexual function and autonomic control of the car-
diovascular system are normal in Fabry patients, which
Table 4: Autonomic function tests.
n Mean (SD) Number of patients with an 
abnormal test result (n)
Inspiratory-Expiratory (I-E) difference bpm 34 19 (8) 3
ΔHRmax bpm 34 25 (10) 3
HRmax/HRmin ratio mmHg 34 1.3 (0.21) 0
ΔSyst 3 min after standing up mmHg 36 3 (9) 0
ΔDiast 3 min after standing up mmHg 36 6 (7) 1
ΔHR 3 min after standing up bpm 36 7 (7) 0
bpm = beats per minuteBiegstraaten et al. BMC Neurology 2010, 10:38
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cast doubt on the general accepted assumption that auto-
nomic neuropathy is a major player in the pathophysiol-
ogy of the disease.
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Figure 1 Inspiratory-Expiratory difference. Circle = male without LVH/cardiomyopathy. Star = male with LVH/cardiomyopathy. Triangle = female 
without LVH/cardiomyopathy. Square = female with LVH/cardiomyopathy.
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